
==== Front
Mediterr J Hematol Infect Dis
Mediterr J Hematol Infect Dis
Mediterranean Journal of Hematology and Infectious Diseases
Mediterranean Journal of Hematology and Infectious Diseases
2035-3006
Università Cattolica del Sacro Cuore

10.4084/MJHID.2024.067
mjhid-16-1-e2024067
Letter to the Editor
MPN/MDS Overlap Syndrome Anticipated by a Severe Bleeding Diathesis: Hypothesis of a Preexisting Platelet Disorder
Ranalli Paola 12
Baldoni Stefano 1
Bruno Daniela 1
Di Ianni Mauro 12
1 Hematology Unit, Pescara Hospital, 65124 Pescara, Italy
2 Department of Medicine and Aging Sciences, University of Chieti-Pescara, 66100 Chieti, Italy
Correspondence to: Paola Ranalli, Department of Medicine and Aging Sciences, University of Chieti-Pescara, 66100 Chieti, Italy. E-mail: paola.ranalli@unich.it
2024
01 9 2024
16 1 e202406711 7 2024
12 8 2024
2024
https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Myeloid Neoplasms
Germline mutations
Bleeding disorders
==== Body
pmcTo the editor.

We report the case of a patient with a conclusive diagnosis of “Myelodysplastic/Myeloproliferative (MDS/MPN) Overlap Syndrome” anticipated by hemorrhagic phenotype. We wonder about the nature of thrombocytopathy shown since bleeding symptoms onset and the possible relationship with oncohematological diagnosis obtained after several years.

Case presentation

A severe bleeding episode occurred after emicolectomy for cancer in a 70-year-old man in 2014. Family and previous personal patient’s history were negative for hemorrhagic diathesis. Basic coagulation tests did not show any alteration; platelet count was normal but associated with mild macrocytic anemia (hb: 12 g/dL; MCV: 101.0 fL) due to folate deficiency (2.6 ng/mL); hemolysis indices were in the normal range. A morphological examination of the blood smear did not show any abnormalities. In an immunophenotyping study on peripheral blood, myeloid precursors accounted for 0.5% of cells.

In 2017, a prostate biopsy was complicated by a further episode of hemorrhage. Blood count resulted in the normal range (Hb: 13.1 g/dL, PLT: 273 × 109/L) as well as coagulation tests (PT: 112%, PTT: 31”; fibrinogen: 336 mg/dL, FVIII: 162 %, vWF:Ag: 205%, vWF:Rco: 200%, FXIII: 96%) except for bleeding time (BT), resulting prolonged (Ivy Method BT: 15.3”) and markedly reduced platelet aggregation to epinephrin 20 micromol (9%).

The patient underwent a prostate biopsy again in 2019 after an infusion of platelet support without pathological bleeding. The same successful prophylaxis was proposed in 2020 (third prostate biopsy) and in 2021 (teeth extractions), in this latter case, with the addition of tranexamic acid.

In 2023, the patient was admitted again at the age of 78 years because of the onset of macrocytic anemia (Hb: 9.7 g/dL, MCV: 114.3 fL) and thrombocytosis (PLT: 894 × 109/L); white blood cells were not altered (WBC: 10.160, N: 8.080 μL−1). LDH was 253 UI/L, EPO: 20.09 mU/mL.

Vitamin levels, iron, hemolysis, and inflammation indices were within the normal range. Following a confusional state, an Encephalic MRI was performed, showing ischemic leukoencephalopathy. The spleen area was at the upper limits of the normal range. On peripheral blood, a JAK2 V617F mutation (55%) and the presence of 0.7% blasts at the immunophenotyping study were detected.

Bone marrow smear showed only modest signs of dyserythropoiesis and myeloid blasts (1% of cells). Perls stain was negative for abnormal iron deposits. The immunophenotyping study did not show aberrant cells; precursors CD34+CD117+ accounted for 0.8% of cells. The cytogenetic test showed 46 XY in 21 metaphases. At histological examination, a marrow fibrosis grade I was detected, and megakaryocytopoiesis was expanded, with no clear signs unequivocally attributable to MDS or MPN.

A next-generation sequencing test was performed, showing mutations of ZRSR2 (86%) and DNMT3A p.C557R (43%). (Table 1). This latter represents one of the most common nondriver mutations in MDS patients but is not frequent in MDS/MPN Syndromes (reported in only 5%).1 However, these mutations can also be found in Essential Thrombocythemia.2 RUNX1, ANKRD26, or ETV6 mutations, associated with the WHO category “myeloid neoplasms with germ line predisposition and preexisting platelet disorders,3 were included in our analysis but not detected.

A conclusive diagnosis of an overlap myelodysplastic/myeloproliferative (MDS/MPN) neoplasm was made, unclassifiable type, with more prominent proliferative features according to JAK2 positivity, platelet count, and bleeding diathesis preceding diagnosis.

A possible MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) was excluded, as ring sideroblasts were not appreciable and spliceosome gene mutations were not detected.

The patient was treated with hydroxyurea (4.5 g/week), resulting in a stable decrease of platelet count below 600 × 109/L. Hemoglobin levels significantly increased with rEPO 30.000 UI/week. An abdomen ultrasound exam showed the stability of the spleen six months after treatment had been started. A platelet aggregation test was repeated, confirming the same abnormalities shown previously. Antiplatelet prophylaxis has not yet been started despite the myeloproliferative aspect of the neoplasm and ischemic encephalopathy.

Certainly, the late onset of bleeding diathesis and the absence of hematologic neoplasms in family members made the hypothesis of a hereditary disease quite unlikely. We did not support the possibility of platelet disorders with a de novo germline predisposition to myeloid neoplasms as our patient was RUNX1/ ANKRD26/ETV6 negative; moreover, in this case, we would have expected a thrombocytopenic rather than a patient with thrombocytosis.

The reduced platelet response to so-called “weak agonists” (epinephrine) could suggest an “aspirin-like syndrome”4 despite normal platelet aggregation in response to arachidonic acid. Serum thromboxane B2 levels would have been useful,5 but they were not available for this patient.

We assumed the more likely hypothesis that platelet dysfunction could be the epiphenomenon of the hematological neoplasm that would have been diagnosed later.

Little information is available about platelet function and its role in many diseases, including MPN.6 However, despite more infrequent than thrombosis, bleeding in MPN represents a more common phenomenon than in the general population7 attributable 1) to a qualitative defect of von Willebrand Factor,8 also in patients with controlled platelet count;9 2) a reduced expression or function of glycoproteins (GpIb or Gp IIb–IIIa);10 3) abnormalities in platelet granules.11 As a consequence, a defective platelet aggregation pattern may be present in MPN, except for arachidonic acid and ristocetin as agonists.10

In conclusion, in this case, the hemorragic phenotype preceded the oncohematological diagnosis, appearing as the epiphenomenomen of the most prominent Myeloproliferative features in the setting of an MDS/MPN Overlap Syndrome.

The long-term outcome of this patient will definitely clarify the hematological diagnosis and the relationship between bleeding and oncohematological diagnosis.

Table 1 Mutations detected at NGS performed on patient peripheral blood in 2023 at diagnosis of myeloid clonal disorder.

Gene name	AA mutation	CDS mutation	Variant Read Frequency	ID Transcript	COSMIC/rs ID	
JAK2	V617F	c.1849G>T	49%	NM_004972.3	COSM12600	
ZRSR2	Splice donor	c.399+1G>A	86%	NM_005089.3	COSM6498506	
DNMT3A	C557R	c.1669T>C	43%	NM_175629.2	COSM1583084	
The complete list of explored genes includes: ABL1, ANKRD26, ARAF, ASXL1, BCOR, BLM, BRAF, CALR, CBL, CREBBP, CSF3R, DDX41, DNMT3A, ERCC6L2, ETV6, EZH2, FLT3, GATA1, GATA2, HRAS, IDH1, IDH2, IK21, JAK2, KDM6A, KIT, KRAS, MAP2K1, MPL, MYD88, NF1, NPM1NRAS, PHF6, PPM1D, PRPF8, PTPN11, RB1, RUNX1SAMD9L, SETBP1, SF3B1, SH2BR, SMC1A, SMC3, SRSF2, STAG2, TET2, TP53, U2AF1, WT1, ZRSR2.

Genomic DNA from peripheral blood was isolated using the Maxwell® system (Promega Corporation, Madison, WI, USA), and a total of 150 ng was used to perform NGS analysis using DNA Prep with custom enrichment panels (Illumina, San Diego, CA) covering 85 leukemia-associated genes. Libraries were sequenced on a Miseq platform (Illumina) using v3 chemistry with 150 bp paired-end configuration.

Raw sequencing data generated were aligned against the Homo sapiens (UCSC hf19) reference with BWA software and analyzed by using the variant interpreter app in BaseSpace Sequence Hub (Illumina).

All samples had a coverage mean of >1000 reads and only variants with an allele frequency (VAF) >5% were described. Synonymous variants and known single nucleotide polymorphisms were excluded (based on an overall population allele frequency >1% according to the gnomAD database).

Table 2 Differential diagnosis: elements in favor or against possible diagnoses.

Possible Diagnosis	In favor	Against	
Inherited Platelet Disorder developing MPN/MDS Overlap Syndrome		Late onset
Family bleeding history
Genetic tests not available	
MDS with Ring Sideroblasts and Thrombocytosis		Bone marrow morphological examination
Spliceosome gene mutations absent
Normal iron deposit at Perls stain	
Myeloid Neoplasm with germline predisposition and pre existing platelet disorder		ANKRD26, ETV6 and RUNX1 mutations absent	
MPN/MDS Overlap Syndrome	Late onset
JAK2 V617F mutation
Macrocytic anemia
Thrombocytosis
Arterial thrombosis
Bleeding as anticipatory symptom		
Aspirin-like Syndrome		Platelet aggregation pattern in response to arachidonic acid
Serum thromboxane B2 levels	

Competing interests: The authors declare no conflict of Interest.
==== Refs
References

1 Palomo L Meggendorfer M Hutter S Twardziok S Ademà V Fuhrmann I Fuster-Tormo F Xicoy B Zamora L Acha P Kerr CM Kern W Maciejewski JP Solé F Haferlach C Haferlach T Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms Blood 2020 136 16 1851 62 10.1182/blood.2019004229 32573691
2 Visconte V Nakashima OM Rogers JH Mutations in Splicing Factor Genes in Myeloid Malignancies: Significance and Impact on Clinical Features Cancers (Basel) 2019 11 12 1844 10.3390/cancers11121844 31766606
3 Arber DA Orazi A Hasserjian R Thiele J Borowitz MJ Le Beau MM Bloomfield CD Cazzola M Vardiman JW The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia Blood 2016 128 3 462 63 10.1182/blood-2016-03-643544 31659364
4 Rolf N Knoefler R Bugert P Gehrisch S Siegert G Kuhlisch E Suttorp M Clinical and laboratory phenotypes associated with the aspirin-like defect: a study in 17 unrelated families Br J Haematol 2009 144 3 416 24 10.1111/j.1365-2141.2008.07468.x 19036102
5 Dragani A Brancati F Pascale S Mattoscio D Rocca B Clinical and laboratory phenotype associated with the aspirin-like defect Br J Haematol 2010 148 4 661 63 10.1111/j.1365-2141.2009.07950.x 19814736
6 Repsold L Joubert AM Platelet Function, Role in Thrombosis, Inflammation, and Consequences in Chronic Myeloproliferative Disorders Cells 2021 10 11 3034 10.3390/cells10113034 34831257
7 Patrono C Rocca B De Stefano V Platelet activation and inhibition in polycythemia vera and essential thrombocythemia Blood 2013 121 10 1701 11 10.1182/blood-2012-10-429134 23335367
8 Castaman G Lattuada A Ruggeri M Tosetto A Mannucci PM Rodeghiero F Platelet von Willebrand factor abnormalities in myeloproliferative syndromes Am J Hematol 1995 49 4 289 93 10.1002/ajh.2830490406 7639273
9 Lancellotti S Dragani A Ranalli P Petrucci G Basso M Tartaglione R Rocca B De Cristofaro R Qualitative and quantitative modifications of von Willebrand factor in patients with essential thrombocythemia and controlled platelet count J Thromb Haemost 2015 Jul 13 7 1226 37 10.1111/jth.12967 25876231
10 Barbui T Cortelazzo S Viero P Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: relationship to platelet number and function Eur J Cancer Clin Oncol 1983 19 11 1593 99 10.1016/0277-5379(83)90091-3 6580171
11 Gerrard JM McNicol A Platelet storage pool deficiency, leukemia, and myelodysplastic syndromes Leuk Lymphoma 1992 8 4–5 277 81 10.3109/10428199209051007 1290957
